Exenatide-study.
Completed
- Conditions
- Type 2 Diabetes Mellitus.
- Registration Number
- NL-OMON26218
- Lead Sponsor
- Eli Lilly and Company, Lilly Nederland BV
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 75
Inclusion Criteria
1. Patients with type 2 diabetes mellitus (m/f);
2. 30-70 years of age;
Exclusion Criteria
1. Use of oral anti-diabetic therapy other than metformine.
2. Clinical significant history or presence of hepatic-, renal-, central nervous system-, gastrointestinal-, haematological- and pulmonary disease;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Glycaemic control and beta-cell function, measured at baseline and after 52 weeks of exenatide or insulin glargine administration.
- Secondary Outcome Measures
Name Time Method 1. Postprandial blood glucose, lipids, lipoproteins and markers of inflammation, coagulation, endothelial function; <br /><br>2. Proportion of subjects with baseline HbA1c >7.0% that achieve HbA1c £7.0%. Proportion of subjects with baseline HbA1c >6.5% that achieve HbA1c £6.5%; <br /><br>3. Seven-point self-monitored blood glucose profiles.